Ichnos Glenmark Innovation (IGI) Presents First Clinical Data from Phase 1 Study of Trispecific TREAT™ Antibody, ISB 2001, Showing High Overall Response Rate (ORR) with Durable Responses and Favorable Safety Profile in Patients with Heavily Pretreated Multiple Myeloma
09 déc. 2024 19h30 HE
|
Ichnos Glenmark Innovation
IGI Presents 1st Clinical Data from Ph 1 Study of Trispecific Antibody, ISB 2001, Showing High ORR & Favorable Safety Profile in Heavily Treated RRMM Pts.
EpimAb Biotherapeutics Announces Oral Presentation for EMB-06 (CND106) First-in-human (FIH) Phase I Study in Multiple Myeloma at the American Society of Hematology (ASH) 2024 Annual Meeting
05 déc. 2024 20h00 HE
|
Shanghai EpimAb Biotherapeutics Co., Ltd.
SHANGHAI, Dec. 06, 2024 (GLOBE NEWSWIRE) -- EpimAb Biotherapeutics, a global clinical stage biotechnology company specializing in the development of bispecific antibodies, is pleased to announce the...
The International Myeloma Foundation Welcomes Four Newly Elected Members to the IMF Board of Directors
26 nov. 2024 08h45 HE
|
International Myeloma Foundation
STUDIO CITY, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) today welcomed four of its newest members to the IMF Board of Directors: Director of Strategic...
Ichnos Glenmark Innovation (IGI) Announces First Presentation of Data from Phase 1 Study of the Trispecific ISB 2001 in Relapsed/Refractory Multiple Myeloma (r/rMM) at Upcoming ASH Annual Meeting
05 nov. 2024 09h00 HE
|
Ichnos Glenmark Innovation
IGI Announces First Presentation of Data from Phase 1 Study of the Trispecific ISB 2001 in Relapsed/Refractory Multiple Myeloma at ASH
Dr. Wenming Chen to Receive Asian Myeloma Network Distinguished Service Award at the 8th AMN Summit in Seoul
17 oct. 2024 10h41 HE
|
International Myeloma Foundation
SEOUL, South Korea, Oct. 17, 2024 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) announced that it will be holding the Asian Myeloma Network (AMN) awards ceremony on Saturday,...
International Myeloma Foundation Launches Clinical Trial Matching Engine in Partnership with SparkCures
10 oct. 2024 08h45 HE
|
International Myeloma Foundation
STUDIO CITY, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) is excited to announce that it has partnered with SparkCures to bring an innovative solution to...
International Myeloma Foundation to Hold First Latin American Myeloma Network Summit in Brazil on September 28
26 sept. 2024 08h45 HE
|
International Myeloma Foundation
RIO DE JANEIRO, Brazil, Sept. 26, 2024 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) is proud to announce that the inaugural IMF Latin American Myeloma Network (LAMN) Summit will be...
International Myeloma Foundation Launches Myelo: The First AI-Powered Responsive Chatbot to Provide Compassionate Myeloma Support for Patients, Care Partners, and Healthcare Professionals
19 sept. 2024 08h45 HE
|
International Myeloma Foundation
STUDIO CITY, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) is proud to announce the launching of Myelo—the first AI-powered responsive chatbot designed to act...
IGI Announces Publication in Nature Cancer on ISB 2001, IGI's Innovative Trispecific Antibody for Relapsed/Refractory Multiple Myeloma
11 sept. 2024 05h00 HE
|
Ichnos Glenmark Innovation
Preclinical data in Nature Cancer showed IGI's ISB 2001 can potentially overcome myeloma cell escape mechanisms to evade therapeutic anti-tumor activity
The International Myeloma Foundation (IMF) Brings Back ‘Do You #kNOwMyeloma?’ for Blood Cancer Awareness Month 2024
29 août 2024 08h45 HE
|
International Myeloma Foundation
LOS ANGELES, Aug. 29, 2024 (GLOBE NEWSWIRE) -- With Blood Cancer Awareness Month coming up this September, the International Myeloma Foundation (IMF) is reviving and amplifying its highly successful...